![](https://stocktraders.online/wp-content/uploads/2025/02/wp-header-logo-1366.png)
U.S. stock futures were higher this morning, with the Dow Jones futures gaining around 150 points on Monday.
Shares of Tesla, Inc TSLA fell in today’s pre-market trading.
Tesla CEO Elon Musk and Vice President of Finance Sendil Palani addressed allegations of the EV company evading taxes in posts on X over the weekend. The company did not evade tax but carried it forward as per an Internal Revenue Service (IRS) provision, they said.
Tesla shares fell 1.2% to $357.16 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
- Pliant Therapeutics, Inc. PLRX dipped 54.5% to $3.54 in pre-market trading after the company issued an update on BEACON-IPF, a Phase 2b/3 trial in patients with idiopathic pulmonary fibrosis.
- Semtech Corporation SMTC shares tumbled 25.2% to $40.75 in pre-market trading. Semtech shares fell around 10% on Friday after Baird cut its price target on the stock from $80 to $60.
- Oriental Rise Holdings Limited ORIS declined 20.2% to $0.91 in pre-market trading after falling more than 5% on Friday.
- Replimune Group, Inc. REPL fell 19.6% to $11.21 in pre-market trading. Replimune announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
- Maze Therapeutics, Inc. MAZE fell 9.5% to $12.11 in pre-market trading. Maze Therapeutics shares gained around 3% on Friday after the company announced that the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients with APOL1 kidney disease.
- Dogness (International) Corporation DOGZ fell 6.6% to $33.00 in pre-market trading.
- The Manitowoc Company, Inc. MTW shares dipped 6.4% to $9.12 in pre-market trading.
- Option Care Health, Inc. OPCH fell 6% to $29.13 in pre-market trading.
- Celestica Inc. CLS fell 3.2% to $125.52 in pre-market trading.
- ON Semiconductor Corporation ON shares declined 2.1% to $50.20 in pre-market trading ahead of quarterly earnings.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.